Summary:
This podcast from the 2023 IO360º conference focuses on key learnings from the full clinical development pathway for approved autologous cell therapy products, from first-in-human, through launch, to commercialization. It explores what worked, what didn't, and what could be done differently in the future for more efficient cell therapy development.
Moderators
Michael Kalos, PhD
Managing Director
Next Pillar Consulting
Speakers
Amir Hefni, PhD, MBA
Global Head, Cell & Gene Therapy
Novartis
Jonathan Jazayeri, PharmD
Executive Director, Global Regulatory Affairs
Kite, a Gilead Company
Jordan Schecter, MD
VP, Cellular Therapy
Janssen Pharmaceuticals
Shivani Srivastava, MD
VP, Development Program Lead, Cell Therapy Development
BMS
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.